Prilenia Therapeutics
Developing New Treatments for Neurodegenerative Diseases
Company Overview
Snapshot
Founded in May 2018, Prilenia Therapeutics operates with 51–200 employees. The company has raised a total of $144.5M across 4 funding rounds from 9 investors. In April 2022, SV Health Investors.
Business overview
Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases and neurodevelopmental disorders. The company's core product, pridopidine, is a first-in-class, oral, highly selective, and potent investigational S1R agonist. Prilenia is currently advancing pridopidine through pre-registration for Huntington's disease (HD) and Phase 3 development for amyotrophic lateral sclerosis (ALS), serving the pharmaceutical and biotechnology sectors within Health Tech & Life Sciences.
Strategic signal
In January 2024, Prilenia Therapeutics announced clinical data supporting its plans to initiate a global Phase 3 study in ALS. This signals a significant advancement in the company's development pipeline for a critical neurodegenerative disease, indicating strong progress towards potential market entry and validating its therapeutic approach for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is Prilenia Therapeutics' primary focus?
- Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders, with an initial focus on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
- What is pridopidine?
- Pridopidine is Prilenia Therapeutics' lead compound, a first-in-class, oral, highly selective, and potent investigational S1R agonist. It is in pre-registration for HD and Phase 3-stage development for ALS.
- When did Prilenia Therapeutics enroll its first patients into the PROOF-HD Phase 3 clinical trial?
- Prilenia Therapeutics enrolled its first patients into its PROOF-HD Phase 3 clinical trial for Huntington's Disease in the United States in October 2020, and in Europe in January 2021.
- Which investors participated in the April 2022 funding round?
- In April 2022, SV Health Investors.
- What regulatory designations has pridopidine received?
- Pridopidine has received Orphan Drug designation for HD and ALS in the U.S. and EU, and Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.